Search

Boehringer Ingelheim hosts Governor Lamont press conference at our Apple Blossom learning center to support more on-site childcare options in Connecticut

Read about Connecticut Governor Ned Lamont and his administration’s visit to our U.S. headquarters in Ridgefield to tour our Apple Blossom Children’s Learning Center, to express the need for more childcare options for local communities and businesses.

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Innovation in Oncology and Cancer Immunology

Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

Sustainable Development for Generations | Boehringer Ingelheim US

At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.

Newsletter Subscription Confirmation

Newsletter : Thank you for subscribing

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.

Boehringer Ingelheim to unveil oncology research at WCLC

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

Management Rotation | Academic Programs

Management Rotation Program

Spain

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

Innovation in Immunology | Human Health | Boehringer Ingelheim US

BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.

A grandmother’s empathy offers a safe space for people with mental health conditions

Supporting the Friendship Bench to improve access to mental healthcare.

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US

Find out how Boehringer Ingelheim is developing vaccines to help North African zoo elephants suffering from deadly infections and illness.

Partnering Culture

BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.

Boehringer included on LinkedIn’s “Top Companies 2024” list

Investing in our people is at the core of what we do

Biberach

Click here to view our Biberach site, in Southern Germany, home to the largest research & development center within Boehringer Ingelheim’s global network.

Your Milestones Drive Ours

Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.

Schizophrenia in real life: Stories of resilience and hope

Discover the reality of life with schizophrenia through the stories of four people who are breaking down the stigma of living with a serious mental illness.

The View from Both Sides of the Table

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers